癌蛋白c—erbB2在乳腺肿瘤患者中过度表达的免疫组化研究

目的检测ｃ－ｅｒｂＢ２蛋白过度表达与乳腺肿瘤患者预后的关系,探讨其作为预后指标的可行性。方法共８５例原发乳腺肿瘤的石蜡切片标本,采用免疫组化方法。结果７例良性病变无１例过度表达;７８例乳腺癌２３例过度表达,表达率为２９．４％;８０％的无淋巴结转移病例未检测到ｃ－ｅｒｂＢ２的过度表达。ｃ－ｅｒｂＢ２蛋白的过度表达在临床Ⅲ期病例中占７１％。ｃ－ｅｒｂＢ２与雌激素受体（ＥＲ）表达呈相反关系的占６７％。该蛋白过度表达与腋淋巴结转移情况未发现相关性（Ｐ＞０．０５）,与临床分期呈显著的正相关（Ｐ＜０．００５）,与ＥＲ呈显著的负相关（Ｐ＜０．００５）。结论ｃ－ｅｒｂＢ２过度表达者预后不良。它可以作为判断乳腺肿瘤患者预后的有效指标,用于临床,辅助判断患者预后,可能具有重要意义。

Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors

OBJECTIVE: To examine the relationship between oncoprotein c-erbB2 over-expression and prognosis of primary breast tumor patients, and find if it can be used as a prognostic indicator. METHODS: Eighty-five cases of paraffin-embedded specimens were used for immunohistochemical study. RESULTS: Over-expression of c-erbB2 was observed in none of the 7 benign breast tumors. Twenty-three out of 78 cases of breast cancer showed over-expression with a positive rate of 29.4%. Over-expressed c-erbB2 oncoprotein was not detected in 80% of patients with negative lymph node. In clinical stage III patients, 71% of them over-expressed c-erbB2. The expression of c-erbB2 and estrogen receptor(ER) was inversely correlated in 67% of breast cancer patients. Oncoprotein c-erbB2 over-expression had no correlation with lymph node status(P > 0.05), but was closely correlated to clinical staging(P < 0.05). CONCLUSION: Patients with over-expression of c-erbB2 oncoprotein showed poor prognosis. The c-erbB2 may be used for predicting the prognosis of breast cancer patients.